TENX
Tenax Therapeutics Inc
$
5.890
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.890
Open
5.890
VWAP
5.89
Vol
242.00
Mkt Cap
24.43M
Low
5.890
Amount
1.43K
EV/EBITDA(TTM)
--
Total Shares
1.96M
EV
-87.01M
EV/OCF(TTM)
--
P/S(TTM)
--
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Show More
4 Analyst Rating
282.00% Upside
Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 22.50 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
282.00% Upside
Current: 5.890
Low
15.00
Averages
22.50
High
30.00
282.00% Upside
Current: 5.890
Low
15.00
Averages
22.50
High
30.00
Guggenheim
Seamus Fernandez
Buy
downgrade
$16 -> $15
2025-05-15
Reason
Guggenheim
Seamus Fernandez
Price Target
$16 -> $15
2025-05-15
downgrade
Buy
Reason
Guggenheim analyst Seamus Fernandez lowered the firm's price target on Tenax Therapeutics to $15 from $16 and keeps a Buy rating on the shares. The firm, which is updating its model following the company's Q1 results, looks forward to the Phase 3 LEVEL readout in 2026. The firm believes this data will be "a major catalyst from which we see the potential for at least a 2x stock move from current levels," the analyst added.
Leerink Partners
David Risinger
Buy
Initiates
$16
2024-10-24
Reason
Leerink Partners
David Risinger
Price Target
$16
2024-10-24
Initiates
Buy
Reason
Leerink analyst David Risinger initiated coverage of Tenax Therapeutics with an Outperform rating and $16 price target. The firm expects shares to rise as the investment community comes to better appreciate the company's lead asset, TNX-103, which is in Phase 3 for PH-HFpEF, or pulmonary hypertension due to heart failure with preserved ejection fraction. Further, Leerink argues that key asset TNX-103 has multibillion dollar sales potential, and it forecasts unadjusted worldwide 2036 sales of $2.2B and 30% probability-adjusted sales of $670M.
Guggenheim
Seamus Fernandez
Strong Buy
Initiates
$16
2024-10-14
Reason
Guggenheim
Seamus Fernandez
Price Target
$16
2024-10-14
Initiates
Strong Buy
Reason
Guggenheim analyst Seamus Fernandez initiated coverage of Tenax Therapeutics with a Buy rating and $16 price target.
William Blair
Matt Phipps
Buy
Initiates
n/a
2024-09-30
Reason
William Blair
Matt Phipps
Price Target
n/a
2024-09-30
Initiates
Buy
Reason
William Blair analyst Matt Phipps initiated coverage of Tenax Therapeutics with an Outperform rating.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tenax Therapeutics Inc (TENX.O) is -1.89, compared to its 5-year average forward P/E of -1.70. For a more detailed relative valuation and DCF analysis to assess Tenax Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.70
Current PE
-1.89
Overvalued PE
-0.42
Undervalued PE
-2.98
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.29
Undervalued EV/EBITDA
-0.23
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.44
Current PS
0.00
Overvalued PS
1.73
Undervalued PS
-0.84
Financials
Annual
Quarterly
FY2025Q1
YoY :
+190.10%
-11.34M
Operating Profit
FY2025Q1
YoY :
+173.98%
-10.41M
Net Income after Tax
FY2025Q1
YoY :
-91.03%
-0.28
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.8K
Volume
1
6-9
Months
28.1K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
3
757.3K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TENX News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
16:12:22
Tenax Therapeutics reports Q1 EPS (28c), consensus (41c)
2025-03-25 (ET)
2025-03-25
16:30:08
Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)
2025-03-05 (ET)
2025-03-05
08:49:11
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement
Sign Up For More Events
Sign Up For More Events
News
8.5
04-16SeekingAlphaTeanx Therapeutics plans secondary offering
8.5
04-15Business InsiderTenax Therapeutics files to sell 4.14M shares of common stock for holders
9.5
03-25NewsfilterTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Sign Up For More News
People Also Watch
NWGL
Nature Wood Group Ltd
1.181
USD
0.00%
DRCT
Direct Digital Holdings Inc
0.413
USD
+1.47%
INAB
IN8bio Inc
2.220
USD
-1.33%
ELBM
Electra Battery Materials Corp
1.170
USD
0.00%
INHD
Inno Holdings Inc
1.230
USD
0.00%
SFHG
Samfine Creation Holdings Group Ltd
0.733
USD
0.00%
SNTI
Senti Biosciences Inc
1.480
USD
0.00%
CDIO
Cardio Diagnostics Holdings Inc
3.700
USD
-1.07%
ERNA
Ernexa Therapeutics Inc
1.690
USD
0.00%
SHFS
SHF Holdings Inc
2.600
USD
+0.39%
FAQ
What is Tenax Therapeutics Inc (TENX) stock price today?
The current price of TENX is 5.89 USD — it has increased 0 % in the last trading day.
What is Tenax Therapeutics Inc (TENX)'s business?
What is the price predicton of TENX Stock?
What is Tenax Therapeutics Inc (TENX)'s revenue for the last quarter?
What is Tenax Therapeutics Inc (TENX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tenax Therapeutics Inc (TENX)'s fundamentals?
How many employees does Tenax Therapeutics Inc (TENX). have?